Gary Patou

This profile gathers the share dealings of Gary Patou in Xenon Pharmaceuticals Inc. Over a trading history stretching from 5 November 2014 to 5 June 2026, the count stands at 34 filings.

Both buying and selling appear: 4 purchases worth €54k, against 10 sales worth €826k. Netting one side against the other leaves €772k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 1 share grant and 14 option exercises. In 2026 alone, the filings show no purchases and 1 sale.

A typical purchase (the median) is worth €12k. Across 3 purchases, this insider has always bought alone, with no colleague buying within 30 days.

Most recently, on 9 June 2026, the filings show an open-market sale worth €44k in Xenon Pharmaceuticals Inc. The last insider purchase was made public on 18 December 2024, 675 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 5 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.